Biocon FY26 results: ₹16,927 cr revenue, 10% dividend

Board clears FY26 audited numbers and key proposals

Biocon Ltd.’s board met on May 7, 2026, to approve the audited financial results for the fiscal year ended March 31, 2026. Alongside the results, the board recommended a final dividend for FY26 and approved steps to increase its ownership in Biocon Biologics Limited (BBL). The meeting also addressed governance items including a change in statutory auditors, board appointments, and an employee long-term incentive plan. The company has scheduled its 48th Annual General Meeting (AGM) for August 6, 2026, to seek shareholder approvals where required. Several of the resolutions, including the dividend and the BBL stake purchase, remain subject to shareholder and other regulatory approvals.

FY26 performance: revenue and profit figures cited

The material provided alongside the filing references more than one set of consolidated FY26 figures. One stated that consolidated FY26 revenue stood at ₹15,261.7 crore and net profit at ₹1,429.4 crore, with FY25 revenue at ₹13,001.7 crore and FY25 net profit at ₹1,201.6 crore. Another stated consolidated FY26 revenue at ₹16,927.0 crore and consolidated net profit at ₹1,429.4 crore. A separate set of numbers in the same material mentioned consolidated net profit of ₹368.8 crore, while also providing “net profit before exceptional items” for FY26 at ₹436 crore. Biocon also reported FY26 total income of ₹17,270 crore and operating revenue of ₹16,927 crore.

Dividend: 10% final payout, record date and timeline

The board recommended a final dividend of 10%, amounting to Re. 0.50 per equity share (face value Rs. 5). The dividend is contingent on shareholder approval at the upcoming AGM. The record date for determining shareholder entitlement is July 3, 2026. The payout is scheduled on or before August 31, 2026, subject to approval. The proposal indicates continuity in returning cash to shareholders while the company works through its group consolidation agenda.

BBL stake purchase: move towards wholly owned subsidiary

A central decision was the approval to acquire approximately 2% of Biocon Biologics Limited (BBL) equity for up to ₹330.73 crore through a special share issuance. The stated objective is to integrate BBL and make it a wholly owned subsidiary, simplifying the group structure and financial reporting. The material notes that Biocon held 98.36% of BBL after a major fundraising in August 2022, with external investors holding 1.64%. The current proposal is designed to purchase shares from minority shareholders and consolidate BBL entirely under Biocon’s direct control. The completion of the stake acquisition is targeted for June 30, 2026, subject to the necessary approvals.

Preferential issue details: share swap mechanics

Biocon outlined a preferential issue linked to the BBL integration. This involves the issuance of up to 87,92,317 equity shares of Biocon at an issue price of Rs. 376.16 per share. The stated purpose is to acquire remaining equity shares from employees and other shareholders through a share swap mechanism. The company positioned this as a step to streamline governance and reporting and to enable a more unified capital allocation strategy. The same disclosure also connected the integration effort to operational synergies across the biosimilars and GLP-1 portfolios.

Auditor change and board refresh

The board approved the appointment of S. R. Batliboi & Associates LLP as statutory auditors for a five-year term, covering 2026-2031, succeeding the previous auditors. Biocon also expanded and refreshed its board. New Independent Directors recommended effective August 1, 2026, include Mr. Rajiv Malik, Mr. Daniel Bradbury, Mr. Peter Baron Piot, Mr. Arun Suresh Chandavarkar, and Ms. Nivruti Rai. Mr. Thomas Jason Roberts has been recommended as a Non-Executive Non-Independent Director. In addition, Dr. Anuj Goel (Chief Development Officer) and Mr. Susheel Umesh (Chief Commercial Officer – Emerging Markets) were designated as Senior Management Personnel.

Trading window, call schedule, and compliance disclosures

Ahead of the results, Biocon filed an intimation under SEBI LODR Regulation 29(1) for the May 7, 2026 board meeting to approve audited Q4 and FY26 results and consider dividend recommendation. The company implemented a trading window closure from April 1, 2026 to May 9, 2026 for insider trading compliance, with reopening on May 10, 2026. Biocon also scheduled an earnings conference call for May 8, 2026 at 09:00 hrs IST via Zoom, with recordings and transcripts to be made available within specified timelines.

Recent regulatory and market updates mentioned

The material also referenced Health Canada’s approval of two denosumab biosimilars on April 3, 2026, disclosed through a press release filed under Regulation 30 on April 21, 2026. Separately, Biocon announced the U.S. launch of Bosaya and Aukelso denosumab biosimilars on April 8, 2026. The compilation also noted a block trade of ₹47.97 crore on NSE at ₹349.00 per share on April 7, 2026.

Key numbers and dates at a glance

Why the combination of actions matters

The decisions combine financial reporting, shareholder payout, and group structure changes into a single FY26 outcome. The dividend and record date provide near-term clarity to shareholders, while the BBL consolidation plan is framed as a longer-term governance and reporting simplification. The auditor change and board appointments expand oversight at a time when the company is executing a stake purchase and a share-based transaction. With stated timelines like June 30 for the acquisition process and the AGM on August 6, several next steps depend on approvals and procedural completion.

Conclusion

Biocon’s May 7 board meeting set the direction for FY26 shareholder actions and a tighter group structure through the planned BBL stake consolidation. The dividend, preferential issue, and governance changes now move to approval and execution milestones, starting with the record date on July 3 and the AGM on August 6, 2026.